Operator: Good afternoon and welcome to the EQRx First Quarter 2023 Financial Results Conference Call. Please be advised that this conference call is being recorded.
Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measuresEuropean Commission decision on marketing. | June 24, 2022